Why Did Regeneron Plunge 7.47%? Earnings Miss, Sales Drop 3.7%

On April 29, 2025, Regeneron's stock experienced a significant drop of 7.47% in pre-market trading, reflecting investor concerns and market sentiment.

Regeneron's first-quarter sales fell short of Wall Street's expectations, with a 3.7% year-over-year decline to $3.03 billion. This miss in revenue targets has raised concerns about the company's financial performance and its ability to meet future earnings expectations.

Regeneron is set to report its earnings, with analysts anticipating a 0.00% Earnings ESP and a Zacks Rank #4 (Sell). The consensus estimate for first-quarter sales and earnings is pegged at $3.28 billion and $3.79 billion respectively, indicating a challenging quarter ahead for the biotech company.

Regeneron is preparing to present 27 abstracts, including eight oral presentations on EYLEA HD® (aflibercept) Injection 8 mg, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. These presentations will provide insights into the real-world use of EYLEA HD in clinical practice, reinforcing the outcomes seen in pivotal trials and highlighting the potential economic benefits of the treatment.